These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21477089

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW.
    Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Nov; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 12. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
    Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Rovers MM, Bont L, Dutch RSV Neonatal Network.
    Eur J Pediatr; 2018 Jan; 177(1):133-144. PubMed ID: 29168012
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [Abstract] [Full Text] [Related]

  • 17. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

  • 18. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE, Mahle WT.
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [Abstract] [Full Text] [Related]

  • 19. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
    Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K.
    An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C, Kauf TL, Saidi AS, Winterstein AG.
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.